Two LabCorp Facilities Withdraw From the HHS National Laboratory Certification Program

Overview

SAMHSA's monthly notice of HHS-certified laboratories records that two Laboratory Corporation of America Holdings facilities — 69 First Ave., Raritan, New Jersey and 1120 Main Street, Southaven, Mississippi — voluntarily withdrew from the National Laboratory Certification Program effective June 30, 2026, and will be omitted from subsequent monthly listings. Employers whose federal workplace or DOT-regulated specimens were routed to either site should confirm their collection vendor now sends to a laboratory that remains certified under the Mandatory Guidelines for Federal Workplace Drug Testing Programs. (91 FR 40548)

This regulatory update carries medium impact for employers nationwide. Below, we cover the key requirements, compliance timeline, practical implications, and recommended next steps.

Key Requirements

Requirements at a Glance

Key provisions of this regulatory update:

1. SAMHSA's monthly notice of HHS-certified laboratories records that two Laboratory Corporation of America Holdings facilities — 69 First Ave., Raritan, New Jersey and 1120 Main Street, Southaven, Mississippi — voluntarily withdrew from the National Laboratory Certification Program effective June 30, 2026, and will be omitted from subsequent monthly listings
2. Employers whose federal workplace or DOT-regulated specimens were routed to either site should confirm their collection vendor now sends to a laboratory that remains certified under the Mandatory Guidelines for Federal Workplace Drug Testing Programs

Compliance deadline: June 30, 2026

Who Is Affected and Where This Applies

This is a federal-level action affecting employers nationwide across all 50 states and U.S. territories.

Industries affected: healthcare, construction, manufacturing, transportation. This update is relevant across multiple sectors. Employers should assess applicability based on their specific workforce, operations, and regulatory exposure.

Compliance Timeline

Background and Context

The Drug Testing Regulatory Landscape

Workplace drug testing regulations have been evolving rapidly across the United States as states move to legalize or decriminalize cannabis. Federal law still classifies marijuana as a Schedule I controlled substance under the Controlled Substances Act, creating tension between state-level protections for off-duty cannabis use and federal workplace safety mandates — particularly for safety-sensitive positions governed by the Department of Transportation.

For employers, this patchwork means that drug testing policies compliant five years ago may now violate state law. The landscape is particularly complex for multi-state employers who must reconcile different rules for pre-employment, random, post-accident, and reasonable-suspicion testing. At the same time, federal agencies like FMCSA and the DOT maintain strict testing requirements that override state cannabis protections for regulated employees such as commercial drivers and pipeline workers.

Why This Matters for Employers

This federal regulatory update affects employers nationwide and represents a meaningful shift in drug testing compliance requirements. While the immediate scope may be limited, it reflects ongoing regulatory attention to this area and may signal further changes.

Cross-industry impact: This update affects employers across multiple sectors, including healthcare, construction, manufacturing, and transportation. Each industry may face different compliance burdens depending on their existing programs and workforce composition. Multi-site employers should coordinate their response across locations to ensure consistent compliance.

For HR directors, safety managers, and compliance officers, this update should trigger a review of current written programs, training records, and standard operating procedures. The cost of proactive compliance is almost always lower than the cost of responding to violations, litigation, or workplace incidents after the fact.

Penalties for Non-Compliance

Non-compliance with drug testing regulations creates financial exposure across multiple channels — from loss of federal contract eligibility under the Drug-Free Workplace Act to fines under 49 CFR Part 40 and state-level employee lawsuits for wrongful termination based on non-compliant testing.

What Employers Should Do Now

BlueHive provides drug testing services nationwide and tracks this topic through our Drug Testing compliance hub.

Frequently Asked Questions

Related Compliance Updates

• AB 2188: Pre-Employment Drug Testing Restrictions for Cannabis — Drug Testing, California (Jan 2024)
• Lawful Off-Duty Activities Protection — Drug Testing, Colorado (Jan 2024)
• Occupational Health Surveillance Program — Occupational Health, Massachusetts (Jan 2025)

---

Source: Agency Guidance · Verified 2026-07-28

This article is part of BlueHive Compliance Watch, which monitors occupational health regulations across all 50 states and federal agencies. Browse all state profiles → · View all compliance articles →